A pilot study on the motor effects of rimantadine in Parkinson's disease

Virgilio Gerald H. Evidente, Charles H. Adler, John N. Caviness, Katrina Gwinn-Hardy

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


The purpose of this pilot study was to determine whether rimantadine, the alpha-methyl derivative of amantadine, might have any antiparkinsonian properties. In an open-label trial, 14 patients (12 de novo and 2 on levodopa treatment) with Hoehn and Yahr stage 2 to 3 Parkinson's disease were placed on rimantadine at doses of 100 to 300 mg/d. No patients had dyskinesias or motor fluctuations. Ten of 14 (71%) reported a mean subjective response of 33% (range 10%-60%) to rimantadine. After treatment, there was a 13% improvement in Hoehn and Yahr staging (p = .01) and a 20% improvement in mean motor Unified Parkinsons Disease Rating Scale scores (p = .02). Rigidity was the most consistently improved feature among the responders. Mean effective dose was 256 mg/d (range 200-300 mg/d). Side effects were mild and transient, with nausea being most common (4/14). We conclude that rimantadine has some motor benefits in Parkinson's disease. A double-blind placebo-controlled study is warranted to validate our findings.

Original languageEnglish (US)
Pages (from-to)30-32
Number of pages3
JournalClinical Neuropharmacology
Issue number1
StatePublished - 1999


  • Amantadine
  • Parkinson's disease
  • Rimantadine

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'A pilot study on the motor effects of rimantadine in Parkinson's disease'. Together they form a unique fingerprint.

Cite this